Tango Therapeutics Stock Forecast

Stock Price Forecast

According to 12 analysts polled by S&P Global, Tango Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $40.45. The average 1-year stock price forecast is 44.62% higher than the current stock price, while the lowest is $24 (-14.19%) and the highest is $69 (+146.69%).

Price Target: $40.45 (+44.62%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$24	$40.45	$36	$69
Change	-14.19%	+44.62%	+28.71%	+146.69%

Analyst Ratings

The average analyst rating for Tango Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	8	9	9	10	9	10
Buy	1	1	1	1	0	0
Hold	1	1	1	1	3	2
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	10	11	11	12	12	12

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Michael Schmidt Guggenheim	Guggenheim	Buy Maintains $32	Buy	Maintains	$32	+14.41%	Jun 10, 2026
Robert Burns H.C. Wainwright	H.C. Wainwright	Buy Reiterates $27 → $66	Buy	Reiterates	$27 → $66	+135.97%	Jun 9, 2026
John Newman Canaccord Genuity	Canaccord Genuity	Buy Maintains $42	Buy	Maintains	$42	+50.16%	Jun 9, 2026
Joseph Catanzaro Mizuho Securities	Mizuho Securities	Buy Reiterates $30 → $36	Buy	Reiterates	$30 → $36	+28.71%	Jun 8, 2026
Kalpit Patel Wolfe Research	Wolfe Research	Buy Upgrades $35	Buy	Upgrades	$35	+25.13%	Jun 8, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

from 62.38M

-100.00%

from 62.38M

Revenue Next Year

3.14M

EPS This Year

-1.32

from -0.87

EPS Next Year

-1.57

from -1.32

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	37.04M	24.86M	36.53M	42.07M	62.38M	-
Revenue Growth	383.83%	-32.89%	46.93%	15.17%	48.29%	-100.00%
Gross Profit	-40.59M	-81.05M	-78.67M	-101.85M	-69.78M	-
Gross Margin	-109.59%	-326.01%	-215.38%	-242.10%	-111.86%	100.00%
Operating Income	-58.19M	-111.07M	-114.17M	-145.60M	-111.29M	-206.37M
Net Income	-58.24M	-108.18M	-101.74M	-130.30M	-101.59M	-194.49M
EPS	-	-	-	-	-0.87	-1.32
Free Cash Flow	-34.02M	-48.74M	-61.82M	-67.27M	-60.86M	-164.00M
No. Analysts	-	-	-	-	-	11

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	n/a
Avg	n/a
Low	n/a

Revenue Growth

Revenue Growth	2026	2027	2028
High	-100.0%
Avg	-100.0%
Low	-100.0%

EPS Forecast

EPS	2026	2027	2028
High	-1.15
Avg	-1.32
Low	-1.44

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-